Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 2c ; Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $70 million versus the consensus estimate of $64.27 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $260-270 million, versus the consensus of $258.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case
• Boeing wins $2 billion satellite contract from DoW